Skip to content

CureVac Netherlands B.V.

CureVac Netherlands B.V.

CureVac Netherlands B.V. is part of CureVac AG: a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA) with the main goal to bring multiple best-in-class mRNA drugs to market. As Antigen Discovery and Validation Center, CureVac Netherlands focuses on developing innovative cancer immunotherapies. We will focus on the design and clinical validation of a first off-the-shelf vaccine targeting a number of shared cancer antigens. In parallel, the antigen discovery technology will be improved and expanded with the goal to develop a platform that enables the detection of all possible antigens expressed by cancer cells. Such platform will form the basis for off-the-shelf and personalized vaccine design for many different cancer types.

 

CureVac Netherlands B.V.
Contactpersoon
Eva Daems
Adres
Science Park 106, Matrix SEVEN
Telefoonnummer

CureVac Netherlands B.V. is part of CureVac AG: a global biopharmaceutical company researching and developing novel drugs based on the natural molecule Messenger RNA (mRNA) with the main goal to bring multiple best-in-class mRNA drugs to market. As Antigen Discovery and Validation Center, CureVac Netherlands focuses on developing innovative cancer immunotherapies. We will focus on the design and clinical validation of a first off-the-shelf vaccine targeting a number of shared cancer antigens. In parallel, the antigen discovery technology will be improved and expanded with the goal to develop a platform that enables the detection of all possible antigens expressed by cancer cells. Such platform will form the basis for off-the-shelf and personalized vaccine design for many different cancer types.

 

Contactpersoon
Eva Daems
Adres
Science Park 106, Matrix SEVEN